Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer
Open Access
- 17 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 25 (7), 579-584
- https://doi.org/10.1634/theoncologist.2019-0570
Abstract
Background Preclinical evidence has demonstrated that common intratumor bacteria metabolize the chemotherapeutic drug gemcitabine. The significance of this bacterial metabolism pathway, relative to the known metabolic pathways by host enzymes, is not known. We hypothesized that bacterial metabolism is clinically significant and that “knockdown” by antibacterial therapy has the unintended effect of increasing the effective dose of gemcitabine, thereby increasing the risk for gemcitabine‐associated toxicities. Materials and Methods We reanalyzed the comparator arm of the MPACT trial (NCT01442974), made available through Project Data Sphere, LLC (CEO Roundtable on Cancer's Life Sciences Consortium, Cary, NC; www.projectdatasphere.org). In this arm, 430 patients with metastatic pancreatic adenocarcinoma were treated with gemcitabine. We used the Anderson‐Gill survival model to compare the risk of developing an adverse event after antibacterial prescription with time unexposed to antibacterials. Adverse events of grade 3 and greater were considered at three levels of granularity: all aggregated into one endpoint, aggregated by class, and taken individually. Antibiotic exposures were analyzed in aggregate as well as by class. Results Antibacterial exposure was associated with an increased risk of adverse events (hazard ratio [HR]: 1.77; confidence interval [CI]: 1.46–2.14), any hematologic adverse event (HR: 1.64; CI: 1.26–2.13), and any gastrointestinal adverse event (HR: 2.14; CI: 1.12–4.10) but not a constitutional (HR: 1.33; CI: 0.611–2.90) or hepatologic adverse event (HR: 0.99; CI: 0.363–2.71). Among specific adverse events, antibacterial exposure was associated with an increased risk of anemia (HR: 3.16; CI: 1.59–6.27), thrombocytopenia (HR: 2.52; CI: 1.31–4.85), leukopenia (HR: 3.91; CI: 1.46–10.5), and neutropenia (HR: 1.53; CI: 1.07–2.17) but not any other specific adverse events. Conclusion Antibacterial exposure was associated with an increased risk of gemcitabine‐associated, dose‐limiting adverse events, including aggregate hematologic and gastrointestinal events, as well as four specific hematologic adverse events, suggesting that intratumor bacteria may be responsible for a clinically significant portion of gemcitabine metabolism. Alternative avenues of evidence will be necessary to confirm this preliminary finding and assess its generalizability. There is plentiful opportunity for similar analyses on other clinical trial data sets, where gemcitabine or other biomimetic small molecules were used. Implications for Practice Patients treated with gemcitabine for metastatic pancreatic ductal adenocarcinoma have an increased rate of gemcitabine‐associated toxicity during and after antibiotic therapy. This observation is consistent with preclinical evidence that intratumor bacteria metabolize gemcitabine to an inactive form. Further research is needed to determine whether this observation merits any changes in clinical practice.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR002489)
- National Institute of Mental Health (F30MH108265)
- NIGMS (2T32GM008719)
This publication has 10 references indexed in Scilit:
- The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?Annals of Oncology, 2019
- Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitorsOncoImmunology, 2019
- 1,520 reference genomes from cultivated human gut bacteria enable functional microbiome analysesNature Biotechnology, 2019
- Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineScience, 2017
- Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)BMC Cancer, 2016
- The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing DataThe Oncologist, 2015
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineThe New England Journal of Medicine, 2013
- Project Data Sphere to Make Cancer Clinical Trial Data Publicly AvailableJNCI Journal of the National Cancer Institute, 2013
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982
- Regression Models and Life‐TablesJournal of the Royal Statistical Society: Series B (Methodological), 1972